Global Information
회사소개 | 문의 | 비교리스트

수포성 표피박리증 : 파이프라인 리뷰

Epidermolysis Bullosa - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 213080
페이지 정보 영문 154 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


수포성 표피박리증 : 파이프라인 리뷰 Epidermolysis Bullosa - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 154 Pages

수포성 표피박리증(EB)이란 선천성 수포성 장애의 일종으로, 무의식의(약간의) 외상에 반응하여 수포가 형성된다는 특징이 있습니다. 주요 증상으로 피부상의 수포 형성, 손가락 및 손톱의 기형·손실, 체내(인후·식도·상부 기도·위·장·요로 등) 수포 형성, 손바닥 및 발뒤꿈치 피부의 각화증(각질증식증), 두피의 수포 출현·반흔화·탈모 등을 들 수 있습니다. 주요 치료법에는 항생제 및 외과 수술 등이 있습니다.

세계 각국에서의 수포성 표피박리증 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

수포성 표피박리증의 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

수포성 표피박리증 : 기업에서 개발중인 치료제

수포성 표피박리증 : 대학/기관에서 연구중인 치료제

수포성 표피박리증 : 파이프라인 제품의 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

수포성 표피박리증 : 기업에서 개발중인 제품

수포성 표피박리증 : 대학/기관에서 연구중인 제품

수포성 표피박리증 치료제 개발에 참여하고 있는 기업

  • Birken AG
  • Fibrocell Science, Inc.
  • GlaxoSmithKline Plc
  • InMed Pharmaceuticals Inc.
  • Karus Therapeutics Limited
  • ProQR Therapeutics N.V.
  • RegeneRx Biopharmaceuticals, Inc.
  • Scioderm, Inc.
  • Stratatech Corporation
  • TWi Pharmaceuticals, Inc.
  • WAVE Life Sciences Ltd.

수포성 표피박리증 : 치료제 평가

  • 단일요법 제품
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

약제 개요

수포성 표피박리증 : 최근 파이프라인 동향

수포성 표피박리증 : 휴지중인 프로젝트

수포성 표피박리증 : 개발이 중지된 제품

수포성 표피박리증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 16.06.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Epidermolysis Bullosa, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Aegle Therapeutics Corp, H1 2020
  • Epidermolysis Bullosa - Pipeline by Almirall SA, H1 2020
  • Epidermolysis Bullosa - Pipeline by Amryt Pharma Plc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, H1 2020
  • Epidermolysis Bullosa - Pipeline by APR Applied Pharma Research SA, H1 2020
  • Epidermolysis Bullosa - Pipeline by Berg LLC, H1 2020
  • Epidermolysis Bullosa - Pipeline by BioVec Pharma Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by BridgeBio Pharma Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Castle Creek Biosciences Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Celularity Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Constant Therapeutics LLC, H1 2020
  • Epidermolysis Bullosa - Pipeline by CSA Biotechnologies LLC, H1 2020
  • Epidermolysis Bullosa - Pipeline by CSL Ltd, H1 2020
  • Epidermolysis Bullosa - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
  • Epidermolysis Bullosa - Pipeline by FIBRX Derm Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Holostem Terapie Avanzate Srl, H1 2020
  • Epidermolysis Bullosa - Pipeline by Immusoft Corp, H1 2020
  • Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by LambdaGen Therapeutics, H1 2020
  • Epidermolysis Bullosa - Pipeline by Mesoblast Ltd, H1 2020
  • Epidermolysis Bullosa - Pipeline by OTR3 SAS, H1 2020
  • Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, H1 2020
  • Epidermolysis Bullosa - Pipeline by Phoenix Tissue Repair Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Quoin Pharmaceuticals Ltd, H1 2020
  • Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by RHEACELL GmbH & Co KG, H1 2020
  • Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, H1 2020
  • Epidermolysis Bullosa - Pipeline by StemRIM Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Therapicon Srl, H1 2020
  • Epidermolysis Bullosa - Pipeline by Trucode Gene Repair Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by TWi Biotechnology Inc, H1 2020
  • Epidermolysis Bullosa - Pipeline by Wings Therapeutics, H1 2020
  • Epidermolysis Bullosa - Dormant Projects, H1 2020
  • Epidermolysis Bullosa - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Epidermolysis Bullosa, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2020, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 12, 3, 2, 11, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Epidermolysis Bullosa - Overview
  • Epidermolysis Bullosa - Therapeutics Development
  • Epidermolysis Bullosa - Therapeutics Assessment
  • Epidermolysis Bullosa - Companies Involved in Therapeutics Development
  • Epidermolysis Bullosa - Drug Profiles
  • Epidermolysis Bullosa - Dormant Projects
  • Epidermolysis Bullosa - Discontinued Products
  • Epidermolysis Bullosa - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q